Fundz

Who to call at Daiichi Sankyo, and when

Fundz watches for the moments Daiichi Sankyo starts buying, and tells you who to reach.

  • An alert the day Daiichi Sankyo raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Daiichi Sankyo, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Daiichi Sankyo. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Daiichi Sankyo and GENESIS Pharma Sign Exclusive Agreement for VANFLYTA® in Central and Eastern Europe.

Jan 07, 2026

Contract Type

agreement

MunichBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharma

Description

Daiichi Sankyo and GENESIS Pharma have entered an exclusive agreement for the distribution and commercialization of VANFLYTA® in 13 markets across Central and Eastern Europe. The agreement aims to enhance access to this innovative treatment for patients with FLT3-ITD positive acute myeloid leukemia.

Company Information

Company

Daiichi Sankyo

Location

Munich, Bavaria, Germany

About

Daiichi Sankyo is a global pharmaceutical company that focuses on innovative and sustainable practices in the development of medicines. The company aims to contribute to the health of patients through its wide-ranging drug development portfolio, particularly in oncology. Additionally, AstraZeneca is a biopharmaceutical company that specializes in the development of medicines for various diseases, with a strong emphasis on oncology research. Both companies are working together to advance treatments for serious medical conditions.

Related People

Hiroyuki
Likely contact at this company
••••••••@••••••••

See Hiroyuki's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Daiichi Sankyo's next move

Learn about Strategic plan

Daiichi Sankyo signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.